By SPC News Staff
The FDA approved epoetin alfa-epbx (Retacrit, Pfizer) as a biosimilar to Epogen/Procrit (epoetin alfa (Epogen/Procrit, Amgen) to treat anemia caused by chronic kidney disease, chemotherapy or use of zidovudine in patients with HIV infection. Epoetin alfa-epbx is approved as a biosimilar, not an interchangeable product.
Epoetin alfa-epbx also is approved for use before and after surgery to reduce the chance that red blood cell transfusions will be needed because of blood loss